Boehringer Ingelheim’s Third Generation EGFR TKI, BI 1482694, Receives FDA Breakthrough Therapy Designation for Treatment of Patients with Non-Small Cell Lung Cancer

… the treatment of non-small cell lung cancer in patients with T790M mutation … EGFR mutation positive non-small cell lung cancer (NSCLC) who failed previous EGFR-tyrosine … (pts) with T790M-positive non-small cell lung cancer (NSCLC) after treatment with an …